Sponsors are looking for reliable data collection methods that enable the continuation of important clinical trials and ensure the safety of clinical trial patients, without requiring them to attend investigative site appointments. ERT is meeting this need with a suite of virtual trial solutions that capture high-quality data from the comfort of patients’ homes.
“We chose to partner with Inofab based on their proven capabilities in meeting respiratory patients’ healthcare needs and their award-winning ultrasonic spirometer, Spirohome,” said Achim Schülke, executive vice president of Respiratory Solutions at ERT. “This partnership enables ERT to further drive innovation in trial virtualization and supports our commitment to offering the best range of trial continuity options, specifically for sponsors developing new respiratory disease treatments.”
Since patients with lung disease are at higher risk for developing more serious complications from the COVID-19 illness, many are likely to avoid clinics or investigative sites to minimize their exposure risk. Together, ERT and Inofab will continue to develop patient-friendly, easy-to-use solutions enabling at-home, patient-administered testing of the lung, supporting patient comfort and safety while ensuring high-quality data collection to keep respiratory trials on track.
“We’re pleased to partner with ERT and to leverage their extensive experience in delivering the important safety and efficacy data sponsors need when developing new respiratory treatments,” said Kerem Yasar, chief technology officer and co-founder of Inofab Health. “Spirohome plays a critical role for endpoint data collection and we’re excited to work with ERT in delivering virtual trial solutions that help clinical trial sponsors continue developing new treatments for the millions of patients living with respiratory disease.”